Thomas Seoh

Thomas Seoh

Thomas Seoh is an entrepreneur/executive who has held senior leadership positions in public and private, pharmaceutical, biotech and medical device companies for over 25 years.  After practicing corporate law in New York and London and serving as General Counsel for several companies, including Viratek in Costa Mesa, which developed the antiviral, VIRAZOLE®, and engaged in antisense oligonucleotide research, he joined Guilford Pharmaceuticals in Baltimore, which commercialized GLIADEL® wafer for glioblastoma multiforme and developed the propofol pro-drug LUSEDRA® and small molecules for Parkinson’s disease.  Thomas began as Guilford's VP, General Counsel and Secretary, and later served as SVP Corporate and Commercial Development.  He was then CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France, developing a repurposed compound in Phase II for Parkinson’s patients, a re-positioned molecule for Duchenne muscular dystrophy and a GPCR drug discover platform.  He also served on the Board of Directors of Arbios Systems, a Cedars Sinai spin-out with an ex vivo liver dialysis device in clinical development.  He has additionally served as President of NexGen Medical Systems of Melbourne, Florida, commercializing a novel mechanical thrombectomy device for Deep Vein Thrombosis and stroke and a state-of-the-art neurocatheter, CEO of Eqalix, a regenerative medicine device company in Reston, VA, developing the first plant-based skin substitute wound dressing, and a member of the Hopkins Alliance, an industry-faculty advisory board at Johns Hopkins School of Medicine.  Thomas holds an AB in Philosophy and History and a JD from Harvard University.